Management of Treatment-Experienced Patients With HIV

  • Author: Eric S. Daar, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 7/13/21 (What's New)

Summary

  • HIV-1 RNA persistently above the limits of assay detection up to 1000 copies/mL is distinct from clinically irrelevant “blips”
  • Initial focus should be to assess adherence and potential for drug–drug or drug–food interactions
  • Considerable data and DHHS guidance support modifying the regimen of treatment-experienced patients with HIV-1 RNA persistently > 200 copies/mL to one of the following switch options[Aboud 2019]

    Action required